Compounds and methods for diagnosis and treatment of viral infections
Inventors
Cope, Frederick O. • Ralph, David A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11007272-B1
Publication Date
2021-05-18
Expiration Date
Abstract
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein. These compositions can be used for diagnosing and/or treating flaviviridae-family viruses including Zika virus, dengue virus, and yellow fever.
Core Innovation
The invention relates to compounds of Formula (II) that include at least one CD206 targeting moiety (R) and at least one therapeutic agent (A), where A can comprise a therapeutic agent, a detection label, or H, and where each X is independently H, L1-A, or L2-R. The compound is characterized by variable linkers (L1 and L2) and an integer n greater than zero, allowing attachment of CD206 targeting moieties and therapeutic or detection components through the linkers.
The document describes dextran-based macromolecular constructs and mannose/DAM constructs including tilmanocept and derivatives as CD206-targeting examples. CD206 is defined as a macrophage C-type lectin receptor, and the constructs are designed to target CD206-high cells using synthetic macromolecules including mannose.
The invention further describes treatment of disease by administering an effective amount of the Formula (II) compound to a subject, including diseases selected from Zika Virus, Yellow Fever, and Dengue Fever, as well as disease caused by infection by a flaviviridae family virus. The described therapeutic configuration includes at least one CD206 targeting moiety and at least one chemotherapeutic agent, including doxorubicin or dexamethasone, as A.
Claims Coverage
The claim set includes three independent claims. Each independent claim centers on administering a Formula (II) compound having at least one CD206 targeting moiety (R) and at least one therapeutic or chemotherapeutic component (A), with disease scope varying by claim.
Treating Zika Virus, Yellow Fever, and Dengue Fever with CD206-targeted Formula (II) compounds
A method of treating a disease by administering an effective amount of a compound of Formula (II) having at least one CD206 targeting moiety (R) and at least one chemotherapeutic agent (A), where the disease is selected from Zika Virus, Yellow Fever, and Dengue Fever.
Targeting Zika virus by targeting macrophages with CD206-targeted Formula (II) compounds
A method of targeting Zika virus by targeting macrophages by administering an effective amount of a compound of Formula (II) having at least one CD206 targeting moiety (R) and at least one chemotherapeutic agent (A) to treat the disease and decrease the amount of disease causing virus.
Treating flaviviridae infections with CD206-targeted Formula (II) compounds carrying doxorubicin or dexamethasone
A method of treating a disease caused by infection by a flaviviridae family virus by administering an effective amount of a compound of Formula (II) having at least one CD206 targeting moiety (R) and at least one A that is doxorubicin or dexamethasone.
Across the independent claims, the core claim coverage is administration of a Formula (II) compound that combines CD206 targeting moieties with chemotherapeutic agents, including doxorubicin or dexamethasone, for treatment of flaviviridae-related diseases, including explicit treatment targets for Zika virus, Yellow Fever, and Dengue Fever, and explicit macrophage/CD206 targeting for Zika.
Stated Advantages
Decreases the amount of disease causing virus when targeting Zika virus.
Provides treatment for diseases selected from Zika Virus, Yellow Fever, and Dengue Fever.
Treats a disease caused by infection by a flaviviridae family virus.
Documented Applications
Diagnosis and/or treatment of Flaviviridae-family viral infections including Zika, dengue, and yellow fever.
Therapeutic use: treating Zika Virus, Yellow Fever, and Dengue Fever by administering Formula (II) compounds with CD206 targeting moieties and chemotherapeutic agents.
Therapeutic use: targeting Zika virus by targeting macrophages and decreasing the amount of disease causing virus.
Therapeutic use: treating disease caused by infection by a flaviviridae family virus using Formula (II) compounds having CD206 targeting moieties and doxorubicin or dexamethasone.
Interested in licensing this patent?